Trials / Completed
CompletedNCT03527160
Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications
Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin to Predict Acute Kidney Injury in Children Research Multiple Nephrotoxic Medications
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 134 (actual)
- Sponsor
- Children's Hospital Medical Center, Cincinnati · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Nephrotoxic medication (NTMx) exposure is one of the most commonly cited causes of acute kidney injury (AKI) in hospitalized children, and is the primary cause of AKI in 16% of cases. Through initial work at Cincinnati Children's Medical Center, NTMx exposure was found to be potentially modifiable and the associated AKI is an avoidable adverse safety event. Currently, only serum Creatinine monitoring is available to monitor for NTMx-associated AKI. The hypotheses of this NINJA NGAL study are that (1) urine NGAL is highly sensitive to detect NTMx-associated AKI, and (2) Bedside test of urine from high risk NTMx-exposed patients are adequate and reliable compared to urine NGAL measured from the clinical platform.
Conditions
Timeline
- Start date
- 2018-04-23
- Primary completion
- 2019-05-31
- Completion
- 2019-06-30
- First posted
- 2018-05-17
- Last updated
- 2021-10-05
- Results posted
- 2021-06-18
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03527160. Inclusion in this directory is not an endorsement.